ENDVEndonovo Therapeutics, Inc.

About Endonovo Therapeutics, Inc. (ENDV)

Endonovo Therapeutics, Inc. (ENDV) is a Biotechnology company headquartered in Woodland Hills, CA, United States whose shares trade over-the-counter on the Pink tier.

Endonovo Therapeutics (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovo's Electroceutical Therapy is FDA-Cleared for the palliative treatment of pain and post-surgical edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Endonovo's Electroceutical Therapy has CMS National Coverage for the treatment of chronic wounds. The Company's current pipeline of clinical-stage Electroceutical Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis.

Products and services

Endonovo Therapeutics (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical® Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovo's Electroceutical® Therapy is FDA-Cleared for the palliative treatment of pain and post-surgical edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Endonovo's Electroceutical® Therapy has CMS National Coverage for the treatment of chronic wounds. The Company's current pipeline of clinical-stage Electroceutical® Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis.

ENDV key facts

Ticker symbol

ENDV

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Woodland Hills, CA, United States

Country of incorporation

US

Employees

16

Estimated market cap

$120.7K (as of May 8, 2025)

Shares outstanding

1,206,614,313

Reporting standard

Alternative Reporting Standard

Audit status

Unaudited

Fiscal year end

12/31

Latest filing

Annual Report (Dec 31, 2024)

Endonovo Therapeutics, Inc. leadership

• Alan Collier — CEO, Interim CFO
• Steven Barnes — Vice President

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with E